| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 207,705 | 211,572 | 192,103 | NaN |
| Cost of revenues | 23,391 | 23,007 | 18,965 | NaN |
| Selling expenses | 66,278 | 64,297 | 58,386 | NaN |
| Marketing expenses | 20,697 | 18,888 | 18,672 | NaN |
| General and administrative expenses | 38,198 | 37,154 | 31,746 | NaN |
| Acquisition-related expenses | NaN | 2,051 | 70,874 | NaN |
| ONAPGO | 261 | 270 | 352 | NaN |
| SPN820 | 1,849 | 2,002 | 1,111 | NaN |
| SPN817 | 16,557 | 3,838 | 4,872 | NaN |
| Qelbree | 2,364 | 1,606 | 3,168 | NaN |
| ZURZUVAE | 82 | 760 | 1,385 | NaN |
| Early Stage Program And Other | 6,565 | 9,061 | 5,173 | NaN |
| Total external development program expenses | 27,678 | 17,537 | 16,061 | NaN |
| Internal employee-related expenses | 11,760 | 10,290 | 13,305 | NaN |
| Total research and development expenses | 39,438 | 27,827 | 29,366 | NaN |
| Other segment items | 21,996 | 42,453 | 9,211 | NaN |
| Net loss | -2,293 | -4,105 | -45,117 | 10,672 |
| Depreciation and amortization | 26,132 | 25,016 | 24,806 | 41,741 |
| Intangible asset impairment charges | NaN | 0 | NaN | NaN |
| Amortization of premium/discount on marketable securities | 192 | -498 | 921 | 1,106 |
| Amortization of deferred financing costs and debt discount | NaN | 0 | NaN | NaN |
| Change in fair value of contingent consideration | 2,391 | 17,759 | 0 | 7,660 |
| Realized loss (gain) from sale of marketable securities | 21 | -439 | NaN | NaN |
| Realized gains from sales of marketable securities | NaN | NaN | 0 | NaN |
| Share-based compensation expense | 8,480 | 9,651 | 7,825 | 15,575 |
| Deferred income tax expense (benefit) | 5,916 | 19,003 | -2,645 | -11,152 |
| Noncash lease expense | 2,258 | 7,980 | NaN | NaN |
| Inventory valuation write-down | 1,815 | 698 | -239 | 1,467 |
| Payment of contingent consideration | 0 | 9,800 | 0 | -4,900 |
| Other noncash adjustments, net | -284 | 5,721 | -3,827 | -3,779 |
| Accounts receivable | -5,619 | 16,419 | 7,131 | -1,246 |
| Inventories | 105 | 4,180 | 12,940 | -9,618 |
| Prepaid expenses and other assets | 12,432 | 6,905 | 11,144 | -4,870 |
| Accrued product returns and rebates | 28,623 | -23,362 | 3,543 | 12,211 |
| Accounts payable and other liabilities | 49 | -491 | -21,528 | -2,547 |
| Net cash provided by operating activities | 66,524 | 19,861 | -61,664 | 89,134 |
| Acquisition of sage, net of cash acquired | NaN | 0 | 293,093 | NaN |
| Purchases of marketable securities | 78,438 | 90,200 | 126,628 | 259,113 |
| Maturities of marketable securities | 59,220 | 39,317 | 468,556 | 266,605 |
| Purchases of property and equipment | 0 | 427 | 129 | 782 |
| Net cash provided by (used in) investing activities | -19,218 | -51,310 | 48,706 | 6,710 |
| Proceeds from credit line | NaN | 0 | NaN | NaN |
| Payments on credit line | NaN | 0 | NaN | NaN |
| Payment on convertible notes | NaN | 0 | NaN | NaN |
| Proceeds from issuance of common stock | 13,670 | 8,557 | 23,741 | 5,318 |
| Employee taxes paid related to net share settlement of equity awards | 4,555 | 31 | 811 | 3,387 |
| Payment of contingent consideration | 0 | 0 | 1,862 | 22,395 |
| Net cash provided by (used in) financing activities | 9,115 | 8,526 | 21,068 | -20,464 |
| Net change in cash, cash equivalents, and restricted cash | 56,421 | -22,923 | 8,110 | 75,380 |
| Cash and cash equivalents at beginning of year | 129,898 | 152,821 | 69,331 | NaN |
| Cash, cash equivalents, and restricted cash at end of year | 186,319 | 129,898 | 152,821 | NaN |
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
SUPERNUS PHARMACEUTICALS, INC. (SUPN)